Candiate: AT-001

Type: Aldose reductase inhibitor

Status: Applied said April 2 multiple investigator-initiated trials were underway to address acute lung inflammation and cardiomyopathy in patients with critical COVID-19. Several New York City hospitals have begun Emergency Investigational Drug applications for AT-001 use in critical COVID-19 patients, through “Named Patient” Emergency INDs or investigator-initiated trials, depending on the patient circumstance and hospital.

Institutions that have initiated trials include The Mount Sinai Hospital, NYU Langone Health, and NewYork-Presbyterian/Columbia University Irving Medical Center. To date, all patients treated under Emergency INDs have demonstrated improvement in cardiopulmonary function, Applied said. AT-001 is in global Phase III development for diabetic cardiomyopathy.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA